Merck, 69450-M, BL21(DE3) Competent Cells - Novagen

General description
A common method for transformation of DNA plasmids into E. coli is the use of chemically competent cells. Although competent cells can be prepared in the laboratory, greater efficiency, reproducibility, and convenience are achieved using Novagen prepared competent cells. Novagen competent cells represent the widest selection available for protein expression. Every Novagen competent cell strain is verified for phenotype and purity, and is guaranteed fortransformation efficiency.
T7 expression strains are lysogens of bacteriophageDE3, as indicated by the (DE3). These hosts carry a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in appropriate T7 expression vectors, using IPTG as an inducer.
BL21 has been the gold standard for protein expression since it was first introduced in 1990. Deficient in lon and ompT proteases, BL21 and its derivatives are ideal for many applications.
BL21(DE3) is a chemically competent E. coli cell suitable for transformation and high level protein expression using a T7 RNA polymerase-IPTG induction system.
This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges us to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.
Other Notes
0.4 ml1 mlComponent

•2 × 0.2 ml5 × 0.2 mlBL21(DE3) Competent Cells

•2 × 2 ml4 × 2 mlSOC Medium

•2 ng2 ngTest Plasmid

Legal Information
NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Multiple Toxicity Values, refer to MSDS (O)